These are the stocks posting the largest moves before the bell.Market Insiderread more
But the bank's net interest margin, a key metric of bank profitability, falls short of expectations.Financeread more
Citi Research has an 18-item checklist to identify whether global markets are entering into a "bear period."Investingread more
The CEO of railroad operator CSX is sounding alarm on the U.S. economy, calling it "unusual" and "puzzling" as it weighs on the company's shipping volumes.Marketsread more
Ascending triangle patterns have been appearing across the stock market, and they tend to be precursors to higher prices, says Miller Tabak's Matt Maley.Trading Nationread more
"Here's what I think is true: Google refused to work for the Pentagon on artificial intelligence" and it works on AI in China, says Richard Clarke.Technologyread more
Buying stocks when they are this expensive has historically led to lower returns, data compiled by Ned Davis Research shows.Marketsread more
Microsoft's effort to catch Amazon Web Services in cloud got a major boost from a new deal with AT&T and an agreement to build out services for 5G.Technologyread more
Uber launches a shopping app with Cargo, an on-the-go convenience store. They already have been working together to put consoles selling snacks in cars.Retailread more
Hedge fund manager Kyle Bass reportedly thinks that U.S. interest rates will plummet toward zero in 2020 as the economy heads for recession.Hedge Fundsread more
If the S&P 500 climbs another 4%, it will have doubled the peak reached in the previous bull market, Michael Santoli notes.Trading Nationread more
Senator Amy Klobuchar echoed on Friday Hillary Clinton's call for a more methodical approach to monitor pharmaceutical companies from increasing drug prices after Mylan grew prices for its auto-injector EpiPen.
The Democratic presidential nominee on Friday released a new plan to fight rising drug prices with a consumer response team. Clinton has been critical of Mylan, even last week sending out a tweet that said in part: "There's no justification for these price hikes."
The U.S. senator from Minnesota said in order for this to happen, you would need economists and experts on the team.
"But what you'd be looking at ... sure there's production and innovation changes sometimes that cause price increases, so you look at that, the value to the patients, the value to the customer," Klobuchar told CNBC's "Power Lunch. "
"But we can't have this situation continue where we are just responding years later realizing these prices have gone up," she said.
Klobuchar on Friday released a statement saying the Centers for Medicare & Medicaid Services found that Mylan had misclassified the EpiPen as a generic drug, resulting in overpayment for the drug by states and the federal government through the Medicaid Drug Rebate Program.
Earlier this week, the senator sent a letter to CMS asking why the device was classified as a generic drug under the program.
Shares of Mylan dropped after the report.
Mylan previously had taken steps to decrease the price of its lifesaving device. After Mylan was scrutinized from Clinton and consumers, the company announced plans to increase access to its leading product by making expansions to its already existing cost-cutting programs.
And on Monday, the company said it would launch the first generic version of the medication at half the price.